Serotonin 5-HT2B receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension

被引:40
作者
Blanpain, C
Le Poul, E
Parma, J
Knoop, C
Detheux, M
Parmentier, M
Vassart, G
Abramowicz, MJ
机构
[1] Free Univ Brussels, Serv Genet Med, B-1070 Brussels, Belgium
[2] Free Univ Brussels, IRIBHN, B-1070 Brussels, Belgium
[3] Free Univ Brussels, Euroscreen SA, B-1070 Brussels, Belgium
[4] Free Univ Brussels, Hop Erasme, Serv Pneumol, B-1070 Brussels, Belgium
[5] Free Univ Brussels, Med Genet Lab, B-1070 Brussels, Belgium
关键词
G-proteins; pulmonary circulation; receptors; serotonin (5-HT); human;
D O I
10.1016/j.cardiores.2003.09.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Appetite-suppressant drug fenfluramine is implicated in primary pulmonary hypertension (PPH) but the molecular pathways that mediate this effect are unknown. A mouse model incriminates the serotonin 5-HT2B receptor but contrasts with other models where this receptor has been shown to mediate pulmonary arterial relaxation via nitric oxide production. Methods: We analyzed the human 5-HT2B gene in 10 patients with appetite-suppressant drug-associated PPH. Results: A mutation causing premature truncation of the protein product was found in one patient. The mutation was not found in 80 control subjects and no 5-HT2B mutation was found in 18 PPH patients not associated with appetite-suppressants. Functional analysis of the transfected receptor expressed either transiently in COS cells or stably in CHO cells demonstrated that the mutated receptor fails to activate the second messenger inositol-phosphates cascade and subsequent intracellular calcium release, in spite of normal expression at the cell membrane. The mutated receptor had no constitutive activity, and produced no dominant negative effect on the wild-type receptor. Conclusion: Loss of serotonin 5-HT2B receptor function may predispose to fenfluramine-associated PPH in man. (C) 2003 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:518 / 528
页数:11
相关论文
共 32 条
[1]   Appetite-suppressant drugs and the risk of primary pulmonary hypertension [J].
Abenhaim, L ;
Moride, Y ;
Brenot, F ;
Rich, S ;
Benichou, J ;
Kurz, X ;
Higenbottam, T ;
Oakley, C ;
Wouters, E ;
Aubier, M ;
Simonneau, G ;
Begaud, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (09) :609-616
[2]   Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor [J].
Atkinson, C ;
Stewart, S ;
Upton, PD ;
Machado, R ;
Thomson, JR ;
Trembath, RC ;
Morrell, NW .
CIRCULATION, 2002, 105 (14) :1672-1678
[3]  
Blanpain C, 1999, BLOOD, V94, P1899
[4]   Palmitoylation of CCR5 is critical for receptor trafficking and efficient activation of intracellular signaling pathways [J].
Blanpain, C ;
Wittamer, V ;
Vanderwinden, JM ;
Boom, A ;
Renneboog, B ;
Lee, B ;
Le Poul, E ;
El Asmar, L ;
Govaerts, C ;
Vassart, G ;
Doms, RW ;
Parmentier, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (26) :23795-23804
[5]   Comparative effect of L-CCG-I, DCG-IV and γ-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes [J].
Brabet, I ;
Parmentier, ML ;
De Colle, C ;
Bockaert, J ;
Acher, F ;
Pin, JP .
NEUROPHARMACOLOGY, 1998, 37 (08) :1043-1051
[6]   Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies [J].
Cortijo, J ;
MartiCabrera, M ;
Bernabeu, E ;
Domenech, T ;
Bou, J ;
Fernandez, AG ;
Beleta, J ;
Palacios, JM ;
Morcillo, EJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 122 (07) :1455-1463
[7]   High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium [J].
Delcroix, M ;
Kurz, X ;
Walckiers, D ;
Demedts, M ;
Naeije, R .
EUROPEAN RESPIRATORY JOURNAL, 1998, 12 (02) :271-276
[8]   Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene [J].
Deng, ZM ;
Morse, JH ;
Slager, SL ;
Cuervo, N ;
Moore, KJ ;
Venetos, G ;
Kalachikov, S ;
Cayanis, E ;
Fischer, SG ;
Barst, RJ ;
Hodge, SE ;
Knowles, JA .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (03) :737-744
[9]  
Du Lingling, 2003, New England Journal of Medicine, V348, P500, DOI 10.1056/NEJMoa021650
[10]   Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension [J].
Eddahibi, S ;
Humbert, M ;
Fadel, E ;
Raffestin, B ;
Darmon, M ;
Capron, F ;
Simonneau, G ;
Dartevelle, P ;
Hamon, M ;
Adnot, S .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (08) :1141-1150